Metalloid Chalcogen Nanoparticles for Universal Medical Isotope Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional approaches to nanoparticle radiolabeling are limited by the need for specific chelators that vary with each radioisotope, leading to difficulties in binding multiple isotopes and stability issues in vivo due to transchelation and detachment of surface-bound chelators, restricting their use to specific isotopes rather than providing a general platform.
Innovation Solution
The use of metal(loid) chalcogen nanoparticles, such as amorphous silica nanoparticles, which can intrinsically bind a wide variety of radioisotopes without additional chelators, facilitating chelator-free radiolabeling and providing a general platform for multiple applications by forming covalent or non-covalent bonds with medical isotopes, ensuring stability and broad applicability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional molecular chelators are used for radiolabeling nanoparticles, then specific radioisotopes can be bound, but the system lacks versatility to bind multiple different radioisotopes and suffers from instability in vivo due to transchelation and detachment
Solution Approach 1:
The patent applies universality by developing a single nanoparticle platform with surface functional groups that can bind multiple different radioisotopes (e.g., 68Ga, 89Zr, 111In, 177Lu) without requiring different chelators for each isotope. The nanoparticle surface is designed with universal binding sites that accommodate various metal ions through coordinate covalent bonding, enabling one system to perform multiple radiolabeling functions.
Solution Approach 2:
The patent extracts and eliminates the need for traditional small molecular chelators from the radiolabeling system. Instead of using separate chelating agents that attach to nanoparticles, the invention incorporates binding functionality directly into the nanoparticle surface through intrinsic surface functional groups, removing the intermediary chelator component that causes transchelation and detachment problems.
2Reliability
If isotope-specific chelators are designed for each radioisotope, then stable binding can be achieved for that specific isotope, but the complexity of the system increases and the process becomes difficult or impossible for many isotopes
Solution Approach 1:
The patent replaces the complex system of multiple isotope-specific chelators with a single universal nanoparticle platform. The surface functional groups on the nanoparticles provide general binding capability for various radioisotopes, eliminating the need to design, select, and modify different chelators for each isotope, thereby reducing system complexity while maintaining binding stability.
Solution Approach 2:
The patent merges the functions of multiple different chelators into a single nanoparticle surface. Instead of having separate chelating agents for each radioisotope, the nanoparticle surface integrates multiple binding modalities that can accommodate different metal ions, combining what would have been multiple separate systems into one unified platform.
3Ease of manufacture
If traditional chelator-based radiolabeling is used, then established labeling protocols can be utilized, but the chelators can be stripped from nanoparticles by endogenous proteins leading to inaccurate biodistribution images
Solution Approach 1:
The patent removes the vulnerable small molecular chelators from the system and replaces them with intrinsic surface-bound functional groups on the nanoparticles. This extraction eliminates the transchelation problem where endogenous proteins strip chelators from the nanoparticle surface, thereby preventing inaccurate biodistribution signals while maintaining ease of radiolabeling through direct surface coordination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for stable and efficient binding of multiple medical isotopes to nanoparticles, enhancing their stability in vivo and enabling their use in various imaging and therapeutic applications without the need for specific chelators, thus overcoming the limitations of traditional methods.
Implementation Method 1
coupling (e.g., via covalent or non-covalent (e.g., chelate) bonds) such metal(loid) chalcogen nanoparticles to medical isotopes
Implementation Method 2
coupling (e.g., via covalent or non-covalent (e.g., chelate) bonds) such metal(loid) chalcogen nanoparticles to medical isotopes
Data Source
AI summary
The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.